Rakovina Therapeutics Inc. (TSXV: RKV; FSE: 7JO0) has completed an upsized private placement that raised aggregate gross proceeds of C$1.991 million to support its preclinical cancer-drug pipeline.
According to the August 31 financing announcement, the company issued 19.91 million units at C$0.10 each across two tranches. Each unit contained one common share and one-half warrant. Each full warrant can be exercised at C$0.20 for 24 months.
The financing was initially capped at C$1.5 million before Rakovina increased it to C$2 million in August. Insiders contributed C$212,000 across the offering. The final tranche remains subject to final acceptance by the TSX Venture Exchange.
Rakovina plans to direct the proceeds primarily toward in-vivo absorption, distribution, metabolism and excretion testing and efficacy studies for kt-5000AI, its dual ATR/mTOR inhibitor program. ATR and mTOR are proteins involved in DNA-damage response, cell growth and survival, making them potential targets in difficult-to-treat cancers.
Funds will also support AI-driven lead optimization through Rakovina’s collaboration with Variational AI, development of its kt-3000 lipid-nanoparticle formulation program, continued work on kt-2000AI and general working capital.
“Completing this upsized financing provides the resources we need to achieve value enhancing milestones,” CEO Kim Oishi said. Rakovina has also stated that it will continue seeking non-dilutive funding from government and industry sources.
The company presented preclinical kt-5000-series results at the American Association for Cancer Research annual meeting in April. A prototype candidate slowed tumor growth in a mouse prostate-cancer model and showed improved tolerability compared with the reference ATR inhibitor ceralasertib. The findings remain preclinical and have not established safety or effectiveness in humans.
Rakovina also presented initial formulation data for a lipid-nanoparticle version of kt-3283, a dual PARP/HDAC inhibitor associated with its kt-3000 program. The company’s planned next steps include additional laboratory and animal testing to assess biological activity, drug behavior and efficacy in tumor models.
The financing addresses a material near-term funding requirement. Rakovina reported only C$200,115 in cash and a C$2.13 million working-capital deficit as of June 30. Its second-quarter net loss decreased to C$1.73 million from C$2.92 million a year earlier, while general and administrative expenses fell approximately 63%. Those financial figures predate the placement.
The offering also creates substantial dilution. The 19.91 million units added the same number of common shares, while their warrants could result in another 9.955 million shares if fully exercised.
Upcoming Catalysts
- In-vivo ADME and efficacy results for kt-5000AI
- Selection or optimization of additional AI-designed lead compounds
- Further kt-3000 lipid-nanoparticle testing
- Continued development of the kt-2000AI program
- Potential pharmaceutical partnerships or non-dilutive funding
Sources
- Rakovina closes upsized C$1.991 million private placement — August 31, 2026
- Rakovina reports Q2 2026 financial results — August 31, 2026
- Rakovina presents preclinical data at AACR 2026 — April 22, 2026
- Rakovina closes first tranche and increases offering — August 12, 2026
Editorial Disclosure
This article is based entirely on publicly available information, including company announcements, securities filings and publicly available corporate sources. Securities discussed or referenced include Rakovina Therapeutics Inc. (TSXV: RKV; FSE: 7JO0). Biotech Stocks Daily has not received compensation from Rakovina Therapeutics, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Confirmed sources include Rakovina’s August 31, 2026 financing and financial-results announcements, its August 12, 2026 first-tranche announcement and its April 22, 2026 preclinical-data release. Scientific findings, development plans and projected milestones originated primarily from Rakovina and have not been independently validated by Biotech Stocks Daily.
Rakovina’s drug candidates remain in preclinical development. The company has not reported human clinical-trial results or regulatory approval for the programs discussed. Results from laboratory and animal studies may not be reproduced in human trials. Additional testing, financing, partnerships and regulatory authorization will be required before any candidate can enter or complete clinical development.
The private placement issued 19.91 million common shares and 9.955 million warrants, resulting in immediate and potential additional dilution. The final tranche remains subject to final TSXV acceptance. Rakovina reported C$200,115 in cash and a C$2.13 million working-capital deficit as of June 30, 2026. Those figures predate the financing, and the C$1.991 million amount represents gross proceeds before applicable fees and expenses.
Financial information is reported in Canadian dollars and reflects the dates of the cited disclosures. No real-time securities prices are included, and readers should verify current market and financial information independently.
Biotechnology securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
